

Claim 29 (new): The use according to claim 27 or 28 for the treatment of Type 2 diabetes.

Claim 30 (new): The according to claim 27 or 28 wherein the glutaminy thiazolidine or glutaminy pyrrolidine, or a pharmaceutically acceptable salt thereof, and the other antidiabetic agent are co-administered or administered sequentially or separately.

Claim 31 (new): The use according to claim 27 or 28 wherein the glutaminy thiazolidine or glutaminy pyrrolidine, or a pharmaceutically acceptable salt thereof, and the other antidiabetic agent are administered orally.

Claim 32 (new): The use according to claim 27 or 28 wherein the glutaminy thiazolidine or glutaminy pyrrolidine, or a pharmaceutically acceptable salt thereof, is glutaminy thiazolidine hydrochloride.

Claim 33 (new): The use according to claim 27 or 28 wherein the other antidiabetic agent is selected from an alpha glucosidase inhibitor, a biguanide, an insulin secretagogue or an insulin sensitiser.

Claim 34 (new): The use according to claim 33, wherein the alpha glucosidase inhibitor is selected from acarbose, emiglitate, miglitol and voglibose.

Claim 35 (new): The use according to claim 34, wherein the alpha glucosidase inhibitor is acarbose.

Claim 36 (new): The use according to claim 33, wherein the biguanide is selected from metformin, buformin and phenformin.

Claim 37 (new): The use according to claim 36, wherein the biguanide is metformin.

Claim 38 (new): The use according to claim 33 wherein the insulin secretagogue is selected from glibenclamide, glipizide, gliclazide, glimepiride, tolazamide and tolbutamide, acetohexamide, carbutamide, chlorpropamide, glibornuride, gliquidone, glisentide, glisolamide, glisoxepide, glycopyramide, glycylamide, glipentide repaglinide and nateglinide.

Claim 39 (new): The use according to claim 33, wherein the insulin sensitiser is a PPARy agonist insulin sensitiser.